Mo Chao-Hua, Gao Li, Zhu Xiao-Fei, Wei Kang-Lai, Zeng Jing-Jing, Chen Gang, Feng Zhen-Bo
Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, 530021 Guangxi Zhuang Autonomous Region China.
Department of Pathology, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou Worker's Hospital, 1 Liushi Road, Liuzhou, 545005 Guangxi Zhuang Autonomous Region China.
Cancer Cell Int. 2017 Sep 25;17:83. doi: 10.1186/s12935-017-0455-1. eCollection 2017.
Ubiquitin-conjugating enzyme E2C (UBE2C) has been previously reported to correlate with the malignant progression of various human cancers, however, the exact molecular function of UBE2C in breast carcinoma (BRCA) remained elusive. We aimed to investigate UBE2C expression in BRCA and its clinical significance.
The expression of UBE2C in 209 BRCA tissue samples and 53 adjacent normal tissue samples was detected using immunohistochemistry. The clinical role of UBE2C was analyzed. Public databases including the human protein atlas and Oncomine were used to assess UBE2C expression in BRCA. Moreover, the cancer genome atlas (TCGA) database was employed to investigate the prognostic value of UBE2C in BRCA.
The positive expression rate of UBE2C in BRCA was 70.8% (148/209), and UBE2C expression in the adjacent breast tissue was negative. The expression of UBE2C was positively correlated with tumor size (r = 0.32, P < 0.001), histological grade (r = 0.237, P = 0.001), clinical stage (r = 0.198, P = 0.004), lymph node metastasis (r = 0.155, P = 0.026), HER2 expression level (r = 0.356, P < 0.001), Ki-67 expression level (r = 0.504, P < 0.001), and P53 expression level (r = 0.32, P = 0.001). Negative correlations were found between UBE2C expression and the ER (r = - 0.403, P < 0.001) and PR (r = - 0.468, P < 0.001) status. UBE2C gene expression data from the public databases all proved that UBE2C was overexpressed in BRCA. According to the TCGA data analysis, a higher positive expression of UBE2C was associated with worse survival of BRCA patients (P = 0.0428), and data from cBioPortal indicated that 11% of all sequenced BRCA patients possessed a gene alteration of UBE2C, predominately gene amplification and mRNA regulation.
Ubiquitin-conjugating enzyme E2C might pose an oncogenic effect on the progression of BRCA.
泛素结合酶E2C（UBE2C）此前已被报道与多种人类癌症的恶性进展相关，然而，UBE2C在乳腺癌（BRCA）中的确切分子功能仍不清楚。我们旨在研究UBE2C在BRCA中的表达及其临床意义。
采用免疫组织化学法检测209例BRCA组织样本和53例癌旁正常组织样本中UBE2C的表达。分析UBE2C的临床作用。利用包括人类蛋白质图谱和Oncomine在内的公共数据库评估BRCA中UBE2C的表达。此外，使用癌症基因组图谱（TCGA）数据库研究UBE2C在BRCA中的预后价值。
BRCA中UBE2C的阳性表达率为70.8%（148/209），而癌旁乳腺组织中UBE2C表达为阴性。UBE2C的表达与肿瘤大小（r = 0.32，P < 0.001）、组织学分级（r = 0.237，P = 0.001）、临床分期（r = 0.198，P = 0.004）、淋巴结转移（r = 0.155，P = 0.026）、HER2表达水平（r = 0.356，P < 0.001）、Ki-67表达水平（r = 0.504，P < 0.001）和P53表达水平（r = 0.32，P = 0.001）呈正相关。UBE2C表达与ER（r = -0.403，P < 0.001）和PR（r = -0.468，P < 0.001）状态呈负相关。公共数据库中的UBE2C基因表达数据均证明UBE2C在BRCA中过表达。根据TCGA数据分析，UBE2C较高的阳性表达与BRCA患者较差的生存率相关（P = 0.0428），来自cBioPortal的数据表明，所有测序的BRCA患者中有11%存在UBE2C基因改变，主要是基因扩增和mRNA调控。
泛素结合酶E2C可能对BRCA的进展具有致癌作用。
